Discouraging trial data broadside Catalyst Biosciences

19 June 2018

Bad news sent shares in Catalyst Biosciences (Nasdaq: CBIO) cratering on Monday, as the Californian hematology specialist revealed that two patients in the ongoing FIX trial developed a neutralizing antibody after treatment with the Factor IX candidate CB-2679d.

The firm is running the Phase I/II trial through its collaborator ISU Abxis (Kosdaq: 086890) in South Korea. While Catalyst stock dropped 64%, ISU shares lost some 15% of their value.

Catalyst said that the antibodies “do not bind to wildtype FIX,” which meant that both patients could resume treatment with their prescribed intravenous FIX prophylaxis therapies. The patients did not experience any bleeds or other safety issues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK